Red Yeast Rice
Red yeast rice genuinely lowers LDL cholesterol — because it contains monacolin K, which is chemically identical to the drug lovastatin. Meta-analyses put the drop at roughly 29-36 mg/dL. That also means it carries statin-like risks, with far worse dose standardisation than a prescription, and in 2025 the EU food safety agency said it could not identify any supplement dose free of safety concern.
Where to buy
-
iHerb Jarrow Formulas, Red Yeast Rice + Co-Q10, 120 Veggie Capsules Ships to 180+ countries · welcome discount for new customers Differs from the studied product: Also contains CoQ10; the trials tested red yeast rice dosed by monacolin K (3–10 mg/day).View on iHerb
Each store sells its own product: check brand, amount and price on the store page before buying. Prices change; the date shows when we last checked.
Referral link — this site may earn a commission on purchases.
What the science says
- Lowers LDL cholesterol Strong evidence
Two meta-analyses of randomised trials agree: a 2023 analysis (24 treatment arms) found LDL fell by about 29 mg/dL versus control, and a 2024 analysis of 14 double-blind trials found about 36 mg/dL, alongside lower total cholesterol. The effect tracks the monacolin K content: products delivering 3-10 mg/day perform like a low-dose statin, and products with negligible monacolin do essentially nothing.
- Who was studied
- Adults with dyslipidaemia or high cholesterol in randomised controlled trials: 24 treatment arms in the 2023 meta-analysis (searched to December 2021) and 14 double-blind trials lasting 4-24 weeks in the 2024 meta-analysis (trials from 2012 to 2022).
- Result
- Change in blood lipids versus placebo or control; LDL and total cholesterol fell in both analyses, while effects on HDL and triglycerides were inconsistent.
- Effect size
- LDL -28.94 mg/dL (95% CI -32.90 to -24.99) and total cholesterol -33.16 mg/dL in 2023; LDL -35.82 mg/dL (95% CI -43.36 to -28.29) and total cholesterol -37.43 mg/dL in 2024. Triglycerides fell by 23.36 mg/dL and HDL rose by 2.49 mg/dL in the 2023 analysis, but neither changed significantly in the 2024 one.
- Limitations
- Trials were short (4-24 weeks) and used products with varying, often unreported monacolin content, so the pooled figure may not match a given shop product; neither abstract reports a risk-of-bias grading.
- Sources
- [1] [2]
- Alternative for people who cannot tolerate statins Moderate evidence
In a 24-week randomised trial in 62 people who had stopped statins because of muscle pain, red yeast rice lowered LDL by 43 mg/dL at 12 weeks versus 11 mg/dL with placebo, without more muscle pain or creatine kinase rises. But the mechanism is identical to a statin, so the reason for intolerance can persist: muscle and liver events appear in pharmacovigilance data, and EFSA judged even low doses capable of causing them.
- Who was studied
- 62 adults with dyslipidaemia who had stopped statins because of myalgia, randomised to red yeast rice 1800 mg twice daily or placebo for 24 weeks alongside a 12-week lifestyle programme; plus US adverse event databases (FAERS, CAERS) and the 2025 EFSA opinion.
- Result
- LDL cholesterol at weeks 12 and 24, with creatine kinase, liver enzymes and pain scores as secondary outcomes; LDL fell more than with placebo and the safety measures did not differ.
- Effect size
- LDL fell by 43 mg/dL at week 12 and 35 mg/dL at week 24 with red yeast rice versus 11 and 15 mg/dL with placebo. In FAERS, red yeast rice accounted for 0.008% of musculoskeletal and 0.01% of hepatobiliary reports from 2013 to 2023.
- Limitations
- The trial was small, single-site and short, and measured laboratory values only. The reassuring adverse event review was written by authors with extensive ties to lipid-drug makers, spontaneous reports cannot give true rates, and EFSA concluded that no safe monacolin intake could be identified.
- Sources
- [3] [4] [5]
- Reduces cardiovascular events (one Chinese extract) Moderate evidence
A 2020 meta-analysis of 7 trials in 10,699 heart attack survivors, dominated by the China Coronary Secondary Prevention Study of the Xuezhikang extract, found fewer nonfatal heart attacks, revascularisations and sudden deaths. The result is consistent but comes from one standardised prescription extract in Chinese patients; no Western commercial supplement has shown event reduction in its own right.
- Who was studied
- 10,699 patients with a previous myocardial infarction and borderline high cholesterol in 7 randomised trials, followed for 4 weeks to 4.5 years, mostly in China with an extract dose of 1,200 mg/day.
- Result
- Nonfatal myocardial infarction, revascularisation, sudden death and blood lipids; all three event types were less frequent with red yeast rice.
- Effect size
- Nonfatal myocardial infarction RR 0.42 (95% CI 0.34 to 0.52), revascularisation RR 0.58 (95% CI 0.48 to 0.71), sudden death RR 0.71 (95% CI 0.53 to 0.94); LDL -20.70 mg/dL.
- Limitations
- The pooled result rests largely on a single large Chinese trial of one prescription-grade extract, run before high-intensity statins were routine; it has not been replicated outside China or with over-the-counter products.
- Sources
- [6]
- Product dose is unreliable Strong evidence
Independent lab tests keep finding the same problem. A US analysis of 12 products, all labelled 600 mg per capsule, found monacolin K ranging from 0.10 to 10.09 mg per capsule and elevated citrinin, a kidney-toxic mycotoxin, in 4. A 2021 EU analysis of 37 supplements found citrinin in every one, including 4 labelled 'citrinin free'. You often cannot know what dose you are actually taking.
- Who was studied
- Products, not people: 12 red yeast rice supplements sold in the US (tested 2006-2008) and 37 supplements sold online and in shops in the EU.
- Result
- Monacolin K and citrinin content measured by liquid chromatography with mass spectrometry, compared with label claims and legal limits.
- Effect size
- US: monacolin K 0.10-10.09 mg per capsule, about a hundredfold range, with citrinin elevated in 4 of 12. EU: citrinin in 37 of 37 (100 to 25100 mcg/kg), only 1 within the current 100 mcg/kg limit; monacolin K 30-83% below the label in 9 products and 10-266% above it in 24; none met the 95-105% content standard required for medicines.
- Limitations
- These are snapshots of specific batches and markets; the US data are over 15 years old and current brands may differ, but no regulator requires medicine-grade content testing for supplements.
- Sources
- [7] [8]
Dosage & safety
How to take it
Interactions
With medications
- statins (atorvastatin, simvastatin and others)
Monacolin K is chemically lovastatin, so the two are additive for muscle and liver toxicity. do not combine — treat red yeast rice as a statin dose
- CYP3A4 inhibitors (clarithromycin, itraconazole, ritonavir, ciclosporin)
These block monacolin K breakdown and can raise blood levels several-fold, risking rhabdomyolysis. do not combine without medical supervision
- fibrates (gemfibrozil, fenofibrate)
Additive risk of myopathy and rhabdomyolysis, as with a prescription statin. do not combine without medical supervision
With other supplements
- berberine
Berberine inhibits CYP3A4 and P-glycoprotein and can raise monacolin K exposure. avoid the combination or use only under medical supervision
- high-dose niacin (above 1 g/day)
Adds to the muscle toxicity risk seen when niacin is combined with statins. do not combine without medical supervision
Well-established interactions only — this is not a complete list. Always tell your doctor and pharmacist what you take.
Frequently asked questions
Does red yeast rice lower cholesterol?
Yes, with strong evidence: red yeast rice lowered LDL by roughly 15-25% in a 2023 meta-analysis, because its monacolin K is chemically identical to lovastatin. Products with negligible monacolin K do essentially nothing.
Is red yeast rice safer than a statin?
No: red yeast rice acts exactly like a low-dose statin, with reported muscle pain, rare rhabdomyolysis and liver toxicity, and its dose is far less reliable, varying more than a hundredfold between brands. Some batches have also contained the kidney toxin citrinin.
Can I take red yeast rice with a statin?
No: do not combine red yeast rice with a prescription statin, since the muscle and liver risks add up. Also avoid combining it with CYP3A4 inhibitors such as clarithromycin, itraconazole or ritonavir, fibrates, berberine or high-dose niacin without medical supervision.
How much red yeast rice should I take?
Trials used red yeast rice supplying 3-10 mg/day of monacolin K with the evening meal, though EU rules now cap supplements under 3 mg per day. Choose a product that states its monacolin K content and tests for citrinin, and tell your doctor you take it.
Scientific references
- Impact of red yeast rice supplementation on lipid profile: a systematic review and meta-analysis of randomized-controlled trials
- Safety and Efficacy of the Consumption of the Nutraceutical "Red Yeast Rice Extract" for the Reduction of Hypercholesterolemia in Humans: A Systematic Review and Meta-Analysis
- Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial
- The Impact of Red Yeast Rice Extract Use on the Occurrence of Muscle Symptoms and Liver Dysfunction: An Update from the Adverse Event Reporting Systems and Available Meta-Analyses
- Scientific Opinion on additional scientific data related to the safety of monacolins from red yeast rice submitted pursuant to Article 8(4) of Regulation (EC) No 1925/2006
- Efficacy of red yeast rice extract on myocardial infarction patients with borderline hypercholesterolemia: A meta-analysis of randomized controlled trials
- Marked variability of monacolin levels in commercial red yeast rice products: buyer beware!
- Risk Assessment of RYR Food Supplements: Perception vs. Reality
Related in Heart & metabolic
- Vitamin B3 (Niacin) Limited evidence
- Vitamin K2 (MK-7) Limited evidence
- Chromium Limited evidence
- Potassium Strong evidence
- Vanadium Limited evidence
- L-Arginine Moderate evidence